BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 28593056)

  • 1. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.
    Neychev V; Kebebew E
    Int J Surg Oncol; 2017; 2017():6424812. PubMed ID: 28593056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Strosberg JR
    CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
    Perez K; Chan J
    Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT; Kunz PL; Reidy-Lagunes DL
    Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Cloyd JM; Konda B; Shah MH; Pawlik TM
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
    Cives M; Strosberg J
    Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
    Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.
    Garcia-Carbonero R
    Cancer Metastasis Rev; 2014 Mar; 33(1):343-4. PubMed ID: 24357057
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors.
    Koffas A; Toumpanakis C
    Expert Opin Drug Saf; 2021 Mar; 20(3):321-334. PubMed ID: 33338383
    [No Abstract]   [Full Text] [Related]  

  • 10. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Raj N; Fazio N; Strosberg J
    Am Soc Clin Oncol Educ Book; 2018 May; 38():292-299. PubMed ID: 30231344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
    Cives M; Soares HP; Strosberg J
    Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.
    Keutgen XM; Schadde E; Pommier RF; Halfdanarson TR; Howe JR; Kebebew E
    Semin Oncol; 2018 Aug; 45(4):232-235. PubMed ID: 30318110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.
    Yoo C; Oh CR; Kim ST; Bae WK; Choi HJ; Oh DY; Lee MA; Ryoo BY
    Cancer Res Treat; 2021 Apr; 53(2):291-300. PubMed ID: 33421978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.
    Garcia-Carbonero R; Sorbye H; Baudin E; Raymond E; Wiedenmann B; Niederle B; Sedlackova E; Toumpanakis C; Anlauf M; Cwikla JB; Caplin M; O'Toole D; Perren A;
    Neuroendocrinology; 2016; 103(2):186-94. PubMed ID: 26731334
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
    Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommended parameters for pathology reporting of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
    Malays J Pathol; 2018 Apr; 40(1):79-82. PubMed ID: 29704389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors.
    Grandhi MS; Lafaro KJ; Pawlik TM
    J Gastrointest Surg; 2015 Dec; 19(12):2273-82. PubMed ID: 26341823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.